This article is more than 5 years old. Information may no longer be current.
VIDEO: Midostaurin, other agents represent therapeutic advances for AML
Recent developments in the management of acute myeloid leukemia, including the FLT3 inhibitor midostaurin, have led to advances for a patient population that has not seen new agents in many years, according to Jonathan M. Gerber, MD, of the Carolinas HealthCare System’s Levine Cancer Institute.
Both midostaurin and azacitidine, another novel treatment for AML, “may end up being particularly useful in elderly patients,” according to Gerber, a HemOnc Today editorial board member. Additional new agents include antibody toxin conjugates and bispecific agents.
“We’ve now seen new agents introduced, many of which work by different mechanisms than previously sought,” Gerber said. “It remains to be seen how much activity any of these agents will have, either as single agents or in combination with other therapies, but these appear to be very promising.”